Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population

British Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2003, Pages 560-569

  Hamdy, Samar I ^a   Hiratsuka, Masahiro ^a,b   Narahara, Kaori ^a   Endo, Naomi ^a   El Enany, Mervat ^c   Moursi, Nadia ^c   Ahmed, Mohammed S E ^c   Mizugaki, Michinao ^a,b  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c NONE

Author keywords

Drug metabolizing enzymes; Egyptians; MDR 1; Pharmacogenetics

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; GENE PRODUCT; GLUTATHIONE TRANSFERASE; METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; SULFOTRANSFERASE 1A1; THIOPURINE S METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ACETYLATOR PHENOTYPE; AFRICAN; ARTICLE; CAUCASIAN; EGYPT; ETHNIC GROUP; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NULL ALLELE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ARYLAMINE N-ACETYLTRANSFERASE; ARYLSULFOTRANSFERASE; BASE PAIR MISMATCH; BASE SEQUENCE; EGYPT; ETHNIC GROUPS; GENE FREQUENCY; GENES, MDR; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; METHYLTRANSFERASES; MOLECULAR SEQUENCE DATA; SULFOTRANSFERASES;

EID: 0038127232     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01786.x     Document Type: Article

References (43)

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
2. Krynetski EY, Tai HL, Yates CR et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 279-290.
3. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphoblastic leukemia. J Pediatr 1991; 119: 985-989.
4. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994; 55: 15-20.
5. Evans DAP. N-Acetyltransferase. Pharmacol Ther 1989; 42: 157-234.
6. Evans DAP, White TA. Human acetylation polymorphism. J Lab Clin Med 1964; 63: 394-403.
7. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79.
8. Nebert DW, Weber WW. Pharmacogenetics. In Principles of drug actions: the basis of pharmacology, 3rd edn, eds Pratt WB, Taylor PW. New York: Churchill Livingstone Inc., 1990; 469-531.
9. Ketterer B, Chirstodoulides LG. Enzymology of cystolic glutathione S-transferase. Adv Pharmacol 1994; 27: 37.
10. Cotton SC, Sharp L, Little J, Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: a huge review. Am J Epidemiol 2000; 151: 7-32.
11. Falany CN. Enzymology of human cystolic sulfotransferases. FASEB J 1997; 11: 206-216.
12. Price RA, Spielman RS, Lucena AL, Van Loon JA, Weinshilboum R.M. Genetic polymorphism for human platelet thermostable phenol sulfotransferase (TS PST) activity. Genetics 1989; 122: 905-914.
13. Weinshilboum RM, Otterness DM, Akosy IA, Wood TC, Her C, Raftogianis RB. Sulfation and sulfotransferases I. Sulfotransferase molecular biology: cDNAs and genes. FASEB J 1997; 11: 3-14.
14. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 1997; 239: 298-304.
15. Gottesman MM, Hrycyna CA, Schoenlein PV, German UA, Pastan I. Genetic analysis of the multidrug transporter. AM Rev Genet 1995; 29: 607-649.
16. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
17. Abdel-Rahman SZ, El-Zein RA, Anwar WA et al. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett 1996; 107: 229-233.
18. Anwar WA, Abdel-Rahman SZ, El-Zein RA, Mostafa HM, Au WW. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 1996; 17: 1923-1929.
19. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-614.
20. Hiratsuka M, Agatsuma Y, Omori F et al. High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5′ nuclease chain reaction assay. Biol Pharm Bull 2000; 23: 1131-1135.
21. Engelke CEH, Meinl W, Boeing H, Glatt H. Association between functional genetic polymorphisms of human sulfotransferases 1A1 and 1A2. Pharmacogenetics 2000; 10: 163-169.
22. Hon YY, Fessing MY, Pui C-H, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8: 371-376.
23. Mcleod HL, Prichard SC, Githang'a J et al. Ethnic differences in thiopurine methyltranseferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999; 9: 773-776.
24. Rossi AM, Bianchi M, Guarnieri C, Barale R, Pacifici GM. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol 2001; 57: 51-54.
25. Loennechen T, Utsi E, Hartz I, Lysaa R, Kildalsen H, Aarabakke J. Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway. Clin Pharmacol Ther 2001; 70: 183-188.
26. Hiratsuka M, Inoue T, Omori F, Agatsuma Y, Mizugaki M. Genetic analysis of thiopurine methyltransferase in a Japanese population. Mutat Res 2000; 448: 91-95.
27. Collie-Dugguid ESR, Prichard SC, Powrie RH et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37-42.
28. Ameyaw MM, Collie-Dugguid ESR, Powrie RH, Ofori-Adjei D, Mcleod HL. Thiopurinemethyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8: 367-370.
29. Tai HL, Krynetski EY, Yates CR et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions defines the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58: 694-702.
30. Bell DA, Taylor JA, Butler MA et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14: 1689-1692.
31. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow-acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4: 125-134.
32. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57: 581-592.
33. Lemos MC, Regateiro FJ. N-acetyltransferase genotypes in the Portuguese population. Pharmacogenetics 1998; 8: 125-134.
34. Okkels H, Sigsgaard T, Wolf H, Autrup H. Aryl N-acetyltransferase1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarker Prev 1997; 6: 225-231.
35. Smith CAD, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 1997; 34: 758-760.
36. Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret J-M. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996; 6: 177-185.
37. Lin HJ, Han C-Y, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics and whites: application to metabolic epidemiology. Am J Hum Genet 1993; 52: 827-834.
38. Mrozikiewicz PM, Drakoulis N, Roots I. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin Pharma Ther 1994; 56: 626-634.
39. Hashem N, Khalifa S, Nour A. The frequency of isoniazid acetylase enzyme deficiency among Egyptians. Am J Phys Anthrop 1969; 31: 97-102.
40. Coughtrie MWH, Glissen RAHJ, Shek B et al. Phenol sulfotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J 1999; 337: 45-49.
41. Carlini EJ, Raftogianis RB, Wood TC et al. Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 2001; 11: 57-68.
42. Ameyaw M, Regateiro F, Li T et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221.
43. Schaeffeler E, Eichelbaum M, Brinkmann U et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358: 383-384.